Loading...
XNAS
STAA
Market cap1.39bUSD
Jul 09, Last price  
27.97USD
1D
-0.64%
1Q
5.79%
Jan 2017
157.79%
Name

STAAR Surgical Co

Chart & Performance

D1W1MN
XNAS:STAA chart
P/E
P/S
5.82
EPS
Div Yield, %
Shrs. gr., 5y
0.66%
Rev. gr., 5y
7.93%
Revenues
239m
-23.72%
56,282,00059,363,00074,894,00075,345,00054,958,00062,765,00063,783,00072,215,00074,987,00077,123,00082,432,00090,611,000123,954,000150,185,000163,460,000230,472,000284,391,000322,415,000313,901,000239,442,000
Net income
-80m
L+298.10%
-15,044,000-15,999,000-23,195,000-6,200,00053,0001,348,000-1,763,000398,000-8,392,000-6,533,000-12,129,000-2,139,0004,968,00014,048,0005,913,00027,511,00039,665,00021,347,000-20,208,000-80,448,000
CFO
-34m
L
-8,647,000-11,184,000-8,228,0001,427,000-4,417,0005,346,0003,217,0003,352,000-7,951,000-2,162,0001,049,0002,853,00012,767,00025,795,00020,951,00043,962,00035,715,00014,594,00015,725,000-34,230,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
IPO date
Feb 24, 1992
Employees
882
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑002024‑122023‑122022‑122021‑122021‑002020‑002018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT